Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan

Abstract Background Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lifethreatening event and one of the important endpoints in clinical trials involving IPF. Despite this, there has been little evaluation of the potential risk factors for AE-IPF in clinical trials. We evaluated th...

Full description

Saved in:
Bibliographic Details
Published inRespiratory investigation Vol. 53; no. 6; pp. 271 - 278
Main Authors Kondoh, Yasuhiro, Taniguchi, Hiroyuki, Ebina, Masahito, Azuma, Arata, Ogura, Takashi, Taguchi, Yoshio, Suga, Moritaka, Takahashi, Hiroki, Nakata, Koichiro, Sugiyama, Yukihiko, Kudoh, Shoji, Nukiwa, Toshihiro
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.11.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a lifethreatening event and one of the important endpoints in clinical trials involving IPF. Despite this, there has been little evaluation of the potential risk factors for AE-IPF in clinical trials. We evaluated the risk factors for AE-IPF in a phase III clinical trial of pirfenidone in Japanese IPF patients. Methods The study population comprised 267 patients. The effects of various baseline characteristics as possible risk factors for AE-IPF during the study, as well as those of a ≥10% decline in percent vital capacity (%VC) within 6 months, were evaluated using Cox׳s proportional hazard model. The ≥10% decline in %VC was calculated in two ways: (1) an absolute decline (e.g. from 60% predicted to 50%); and (2) a relative decline (e.g. from 60% predicted to 54%). Results Over 52 weeks, 14 patients experienced AE-IPF. Univariate analysis using Cox׳s proportional hazards model showed that both relative and absolute ≥10% decline in %VC within 6 months were significant risk factors for AE-IPF. Stepwise multivariate analysis demonstrated that absolute or relative decline in both %VC and alveolar to arterial oxygen pressure difference (AaDO2 ) were significant risk factors for AE. The model using absolute decline [Hazard Ration (HR)=7.405, p =0.0007] and baseline AaDO2 (HR=1.063, p =0.0266) had a better fit than the model using relative decline and baseline AaDO2. Conclusions Rapid %VC decline (≥10% within 6 months), and high baseline AaDO2 , may be risk factors for AE-IPF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2212-5345
2212-5353
DOI:10.1016/j.resinv.2015.04.005